Blast

Status
Start Date
Condition
Estimated
enrollment
Age Range
Phase
Study Type

Objective

To learn if the investigational uses of two drugs - BG00012 (dimethyl fumarate) and BIIB017 (peginterferon beta-1a) - are safe and effective for children with RMS.

The investigational drugs

BG00012 is thought to work by reducing the inflammation caused when the immune system attacks nerve cells. The mechanism of action of BIIB017 in MS is not currently fully understood, but is thought to work by reducing the inflammation caused by MS, which may potentially slow the progression of the condition and help to prevent relapses.

Key eligibility criteria

  • Children and adolescents
  • 10-17 years old
  • Confirmed RMS
  • Have evidence of disease activity defined as either:
    • Active lesions seen on an MRI scan within the last six months
    • At least one relapse within the last year
    • At least two relapses within the last two years

Trial length

  • Approximately 2 years